Katagiri, S.; Akahane, D.; Otsuki, S.; Suto, A.; Yamada, A.; Suguro, T.; Asano, M.; Yoshizawa, S.; Tanaka, Y.; Furuya, N.;
et al. Tyrosine Kinase Inhibitors Do Not Promote a Decrease in SARS-CoV-2 Anti-Spike IgG after BNT162b2 Vaccination in Chronic Myeloid Leukemia: A Prospective Observational Study. Vaccines 2022, 10, 1404.
https://doi.org/10.3390/vaccines10091404
AMA Style
Katagiri S, Akahane D, Otsuki S, Suto A, Yamada A, Suguro T, Asano M, Yoshizawa S, Tanaka Y, Furuya N,
et al. Tyrosine Kinase Inhibitors Do Not Promote a Decrease in SARS-CoV-2 Anti-Spike IgG after BNT162b2 Vaccination in Chronic Myeloid Leukemia: A Prospective Observational Study. Vaccines. 2022; 10(9):1404.
https://doi.org/10.3390/vaccines10091404
Chicago/Turabian Style
Katagiri, Seiichiro, Daigo Akahane, Shunsuke Otsuki, Arisa Suto, Akiko Yamada, Tamiko Suguro, Michiyo Asano, Seiichiro Yoshizawa, Yuko Tanaka, Nahoko Furuya,
and et al. 2022. "Tyrosine Kinase Inhibitors Do Not Promote a Decrease in SARS-CoV-2 Anti-Spike IgG after BNT162b2 Vaccination in Chronic Myeloid Leukemia: A Prospective Observational Study" Vaccines 10, no. 9: 1404.
https://doi.org/10.3390/vaccines10091404
APA Style
Katagiri, S., Akahane, D., Otsuki, S., Suto, A., Yamada, A., Suguro, T., Asano, M., Yoshizawa, S., Tanaka, Y., Furuya, N., Fujimoto, H., Okabe, S., Gotoh, M., Ito, Y., & Gotoh, A.
(2022). Tyrosine Kinase Inhibitors Do Not Promote a Decrease in SARS-CoV-2 Anti-Spike IgG after BNT162b2 Vaccination in Chronic Myeloid Leukemia: A Prospective Observational Study. Vaccines, 10(9), 1404.
https://doi.org/10.3390/vaccines10091404
